Predicting liver cancer after hepatitis C cure
Part of Cancer, Digestive system clinical trials.
This study looks at what factors predict liver cancer (HCC) in people with HCV-related cirrhosis after they've been cured of hepatitis C. It compares those who developed HCC soon after cure to those who didn't, to find clues for better monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have liver cirrhosis caused by hepatitis C (HCV), not by other causes.
- You must have achieved a sustained virologic response (SVR12) after taking direct-acting antivirals (DAAs).
- If you are a case patient, you must have been diagnosed with hepatocellular carcinoma (HCC) on or before June 30, 2025, by imaging or biopsy.
- You cannot have had HCC diagnosed less than 6 months before achieving SVR, or have a combined HCV-HBV cirrhosis, or have a bile duct cancer (cholangiocarcinoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
This study uses non-invasive tests, like scans or blood tests, to predict how well people with liver cancer (hepatocellular carcinoma, or HCC) will do after curative treatment. It may help doctors better understand your condition without needing invasive procedures.
This trial looks at how well a prediction model can estimate the chances of successfully shrinking liver cancer with certain treatments. It includes patients with larger or multiple tumors in the liver, as long as the cancer has not spread to other parts of the body.
This study asks liver doctors (hepatologists) about their knowledge and views on new ways to predict liver cancer in hepatitis C patients who were cured with antiviral pills. Your answers can help improve cancer screening.
This study uses patient data to build a model that predicts the chance of developing liver cancer in people with chronic hepatitis B who are on antiviral treatment. It aims to help doctors identify who might need closer monitoring.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.